AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

2月20日，阿斯利康（AstraZeneca）宣布与珐博进有限公司（FibroGen）达成协议，计划以约1.6亿美元（约合11.6亿元人民币）收购珐博进中国。 根据协议条款，珐博进将获得8500万美元的企业价值，以及交易完成时珐博进中国持有的约7500万美元现金，合计约1.6亿美元。预计该交易将在2025年中期完成，具体时间将取决于包括中国监管审查在内的常规交割条件。 交易完成后，阿斯利康将获得罗 ...

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

FibroGen (NASDAQ:FGEN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the ...

By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...

AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...

The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

This brief covers various health news including U.S. FDA's misinterpreted banned words policy, New York's lawsuit against vape distributors for targeting teens, President Trump's meeting with pharma ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...